{"id":"camrelizumab-and-cetuximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Rash/acneiform dermatitis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201577","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T13:20:50.688322","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Camrelizumab is a PD-1 inhibitor that releases immune checkpoint inhibition, allowing T cells to attack tumor cells. Cetuximab is an EGFR-targeting monoclonal antibody that blocks growth signaling and antibody-dependent cellular cytotoxicity. The combination leverages both immune activation and direct anti-tumor mechanisms.","oneSentence":"Camrelizumab blocks PD-1 to enhance immune response while cetuximab blocks EGFR to inhibit tumor cell growth, combining immunotherapy with targeted therapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:44.064Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Head and neck squamous cell carcinoma (Phase 3)"},{"name":"Nasopharyngeal carcinoma (Phase 3)"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT07432087","phase":"PHASE3","title":"Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Yue He, MD","startDate":"2026-02-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":246},{"nctId":"NCT05673577","phase":"PHASE2","title":"Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-03-22","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":40},{"nctId":"NCT07059949","phase":"PHASE2","title":"Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-30","conditions":"Unresectable Metastatic Rectal Cancer, CAPOX, Combination of Radioimmunotherapy","enrollment":80},{"nctId":"NCT05019534","phase":"PHASE1","title":"Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2021-08-15","conditions":"BRAF V600E-mutated /MSS Metastatic Colorectal Cancer, Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Camrelizumab and Cetuximab","genericName":"Camrelizumab and Cetuximab","companyName":"Yue He, MD","companyId":"yue-he-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camrelizumab blocks PD-1 to enhance immune response while cetuximab blocks EGFR to inhibit tumor cell growth, combining immunotherapy with targeted therapy. Used for Head and neck squamous cell carcinoma (Phase 3), Nasopharyngeal carcinoma (Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}